• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@Muğla
  • Fakülteler
  • Tıp Fakültesi
  • Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
  • View Item
  •   DSpace@Muğla
  • Fakülteler
  • Tıp Fakültesi
  • Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Endogenous Fungal Endophthalmitis in a Patient Admitted to Intensive Care and Treated with Systemic Steroid for COVID-19

Thumbnail

View/Open

Karalezli.pdf (159.6Kb)

Date

2022

Author

Kaderli, Sema Tamer
Karalezli, Aylin
Çitil, Burak Ekrem
Saatçi, Ali Osman

Metadata

Show full item record

Citation

Kaderli ST, Karalezli A, Çitil BE, Saatci AO. Endogenous Fungal Endophthalmitis in a Patient Admitted to Intensive Care and Treated with Systemic Steroid for COVID-19. Turk J Ophthalmol. 2022 Apr 28;52(2):139-141. doi: 10.4274/tjo.galenos.2022.04324. PMID: 35481735.

Abstract

A 61-year-old woman presented to our clinic with complaints of decreased visual acuity, pain, and redness in her left eye. Best corrected visual acuity (BCVA) was 20/20 in the right eye and counting fingers at 3 meters in the left eye. On slit-lamp examination, 1+ cells were detected in the anterior chamber. Fundus examination revealed 1+ haze in the vitreous and multiple creamy-whitish lesions in the retina and vitreous. Her history included a diagnosis of coronavirus disease 2019 (COVID-19) one month earlier, for which she was hospitalized in the intensive care unit for 20 days and received systemic corticosteroid treatment. Vitreous culture yielded Candida albicans. The patient's nasopharyngeal swab sample was positive for COVID-19 by reverse transcription polymerase chain reaction test. BCVA was improved to 20/40 after amphotericin therapy (via intravitreal injection and intravenous routes), and the vitritis and chorioretinitis lesion regressed after 2 weeks of treatment. Two weeks later, intravenous amphotericin was discontinued and oral fluconazole treatment was started at a dose of 400 mg/day. At 3-month follow-up, her BCVA was 20/25 and no inflammatory reaction was observed in the anterior chamber and vitreous.

Source

Turk J Ophthalmol

Volume

52

Issue

2

URI

https://hdl.handle.net/20.500.12809/9955

Collections

  • Cerrahi Tıp Bilimleri Bölümü Koleksiyonu [543]
  • PubMed İndeksli Yayınlar Koleksiyonu [2082]
  • WoS İndeksli Yayınlar Koleksiyonu [6466]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Policy | Guide | Contact |

DSpace@Muğla

by OpenAIRE
Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeInstitution AuthorThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeInstitution Author

My Account

LoginRegister

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Policy || Guide|| Instruction || Library || Muğla Sıtkı Koçman University || OAI-PMH ||

Muğla Sıtkı Koçman University, Muğla, Turkey
If you find any errors in content, please contact:

Creative Commons License
Muğla Sıtkı Koçman University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@Muğla:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.